The Chinese Insulin business is going going ' gang busters', it would not be surprising to see income from that business increased by another US $1 mill over the results for 2016.
Reports from China indicate the incidence of cancer , heart disease and diabetes are severely under diagnosed and under treated. There is no reason the that Insulin treatment will not increase quickly.
What will the majority shareholder do with SIE ? It makes little sense to own 95+% , it would be cleaner and cheaper to privatise SIE.
SIE is in very competitive low price markets in Asia especially Korea and Vietnam, SIE will always have difficulties in competing in these market with expensive high quality pharmaceuticals from Europe.
The price target for SIE must be 0.20 c
SIE Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
